In Part 1, Dr. Bailey discusses the origins of Juvenescence as well as his belief that the nascent longevity industry is reaching an inflection point. Greg stresses that Juvenescence does not hold the sole aim of increasing lifespan; the main priority is to increase
In Part 2, he discusses democratising healthcare, paradigm shifts and disruptive technologies. Dr. Bailey shares his insights on educating investors on the longevity field, how healthcare is going to be personalized – and democratized – in the future, and which types of investors see the most potential in longevity.
Read Part 1 at Longevity Technology.
Read Part 2 at Longevity Technology.